Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantJH
Janus Henderson Investors
Activity from announced rounds
Activity in this selectionOct 6, 2026 · Jul 9, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.2B 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionFORM ENERGY
Long-duration iron-air batteries designed to store electricity for multi-day grid needs.
$750MSeries G
ParticipantEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedDraig Therapeutics
Developing transformative, best-in-class neuropsychiatric therapies
$65MSeries B
Role not disclosed